Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?
Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.
Pharma & Biotech
Pharma & Biotech
Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.